Study Summary
This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.
Interested in this trial?
Submit an InquiryInterventions
JCAR017GENETIC
No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.
JCARH125GENETIC
No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| City of Hope | Duarte | California | United States |
| Massachusetts General Hospital | Boston | Massachusetts | United States |